Treatment of Prostate Cancer With Firmagon®

• Status: Completed
• Trial end date: 2015-09-24
• Target enrollment: 0
• Participant gender: Male

Summary

How are testosterone levels of patients with prostate cancer under treatment with Firmagon® changing.

Former studies showed a quick fall of testosterone levels after start of therapy with Firmagon® and a quick recovery when therapy is stopped. The investigators want to prove this in a normal outpatient urologist setting. Furthermore data is collected to prove the adherence to the German S3-Guideline for the treatment of prostate cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: United Clinic Management GmbH

Criteria

Inclusion Criteria:

• advanced hormone-dependent prostate cancer with no other previous hormone therapy for whom - irrespectively of this NIS -the use of Firmagon® is intended

Exclusion Criteria:

• contraindication for Degarelix